The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | Risk stratification and personalized treatment in HL
Igor Aurer, MD, PhD, University of Zagreb, Zagreb, Croatia, provides an overview of risk stratification in patients with Hodgkin lymphoma (HL). Prof. Aurer describes criteria outlined by The German Hodgkin Study Group which determines treatment options for patients with favorable and unfavorable HL. Patients with favorable HL are treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy, whereas treatment for unfavorable HL can involve more intensive chemotherapy or less intensive chemotherapy such as ABVD therapy with radiotherapy. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
